Page last updated: 2024-08-21

adamantane and Cardiac Failure

adamantane has been researched along with Cardiac Failure in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	39 (95.12)	24.3611
2020's	2 (4.88)	2.80

Authors

Authors	Studies
Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD	1
Orime, K; Terauchi, Y	1
Gallo, M; Giaccari, A; Mannucci, E; Monami, M; Montereggi, C; Nreu, B; Ragghianti, B	1
Kaneko, M; Narukawa, M	1
Bhatt, DL; Braunwald, E; Im, K; Kanevsky, E; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Sjöstrand, M; Stahre, C; Steg, PG; Udell, JA	1
Bowman, B; Cobretti, MR; Grabarczyk, T; Potter, E	1
Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB	1
Cobb, MS; Emter, CA; Fleenor, BS; Hiemstra, JA; Minervini, G; Olver, TD; Ouyang, A	1
Asakura, M; Asano, Y; Asanuma, H; Ishibashi-Ueda, H; Ito, S; Kitakaze, M; Liao, Y; Min, KD; Minamino, T; Mochizuki, N; Sanada, S; Shindo, K; Takahashi, A; Takashima, S; Yamazaki, S; Yan, Y	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Desai, NR; Frederich, R; Hirshberg, B; Hoffman, EB; Leiter, LA; McGuire, DK; Mosenzon, O; Ohman, P; Ray, KK; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Wiviott, SD	1
Smahelová, A; Spinar, J	1
Dicembrini, I; Mannucci, E; Monami, M	1
Fonarow, GC	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Frederich, R; Hirshberg, B; Im, K; Jarolim, P; Lewis, BS; McGuire, DK; Morrow, DA; Mosenzon, O; Pollack, PS; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA	1
Gilbert, RE	1
Clifton, P	1
Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA	1
Dangi-Garimella, S	1
Bhatt, DL; Bonnici, F; Braunwald, E; Cahn, A; Frederich, R; Hirshberg, B; Kumar, KM; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Smahelova, A; Stahre, C; Teoh, H	1
Delivanis, DA; Montori, VM	1
Federici, M; Kappel, BA; Marx, N	1
Del Prato, S; Evans, M; Kothny, W; Lukashevich, V; McInnes, G; Schweizer, A; Shao, Q; Stumvoll, M	1
Muskiet, MH; Tonneijck, L; van Raalte, DH	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Frederich, R; Hirshberg, B; Im, K; Jarolim, P; Lewis, BS; McGuire, DK; Morrow, DA; Mosenzon, O; Pollack, PS; Raz, I; Scirica, BM; Steg, G; Udell, JA; Umez-Eronini, AA	1
Bhatt, DL; Braunwald, E; Cahn, A; Cavender, MA; Davidson, J; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG	1
Špinar, J; Špinarová, L; Vítovec, J	1
Cappell, K; Cole, AL; Fowler, R; Fu, AZ; Ghannam, A; Johnston, SS; Kalsekar, I; Riehle, E; Sheehan, J; Tsai, K	1
Baker, WL; White, WB	1
Chaiyakunapruk, N; Dilokthornsakul, P; Kongwatcharapong, J; Nathisuwan, S; Phrommintikul, A	1
Jermendy, G	1
Antonazzo, IC; De Ponti, F; Koci, A; Marchesini, G; Poluzzi, E; Raschi, E	1
Balakrishnan, S; Brown, NJ; Fireman, BH; Graham, DJ; Griffin, MR; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Nathwani, N; Pimentel, M; Pucino, F; Reichman, ME; Rucker, M; Toh, S	1
Caffrey, JL; Chang, CH; Chang, YC; Chuang, LM; Lai, MS; Lin, JW; Wu, LC	1
Cebrián-Cuenca, AM; Consuegra-Sánchez, L; Franch-Nadal, J; Navarro-Pérez, J; Núñez-Villota, J; Orozco-Beltrán, D	1
Scirica, BM	1
Cahn, A; Raz, I; Schernthaner, G	1
Álvarez-Guisasola, F; Cebrián Cuenca, AM; Consuegra-Sánchez, L; Navarro Pérez, J; Núñez Villota, J; Orozco Beltrán, D	1
Kompa, AR; Krum, H; Tran, L; Wang, BH	1
de Boer, RA; Meissner, M; Silljé, HH; van Gilst, WH; Yin, M	1
Bellien, J; Bounoure, F; Dreano, Y; Glevarec, E; Lucas, D; Merabet, N; Mulder, P; Nicol, L; Remy-Jouet, I; Thuillez, C; Wecker, D	1

Reviews

11 review(s) available for adamantane and Cardiac Failure

Article	Year
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:17 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2020
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 09-22, Volume: 31, Issue:10 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Time Factors; Treatment Outcome	2021
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:7 Topics: Acute Disease; Adamantane; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors	2014
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clinical therapeutics, 2014, Dec-01, Volume: 36, Issue:12 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin	2014
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:8 Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones	2015
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11 Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Vildagliptin	2015
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:11 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Sitagliptin Phosphate; Uracil	2015
Cardiovascular Effects of Incretin-Based Therapies. Annual review of medicine, 2016, Volume: 67 Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil	2016
Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. International journal of cardiology, 2016, May-15, Volume: 211 Topics: Adamantane; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2016
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials]. Orvosi hetilap, 2016, Apr-17, Volume: 157, Issue:16 Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil	2016
Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria. Revista espanola de cardiologia (English ed.), 2017, Volume: 70, Issue:12 Topics: Adamantane; Causality; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Proportional Hazards Models	2017

Trials

7 trial(s) available for adamantane and Cardiac Failure

Article	Year
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. JAMA cardiology, 2018, 02-01, Volume: 3, Issue:2 Topics: Adamantane; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Incretins; Male; Renal Insufficiency, Chronic	2018
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14 Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatitis	2013
[SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:11 Topics: Adamantane; Aged; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis	2013
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 2014, Oct-28, Volume: 130, Issue:18 Topics: Adamantane; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Risk Assessment; Troponin T	2014
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes care, 2015, Volume: 38, Issue:4 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome	2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes care, 2015, Volume: 38, Issue:6 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome	2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. The American journal of medicine, 2016, Volume: 129, Issue:3 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Risk; Stroke	2016

Other Studies

23 other study(ies) available for adamantane and Cardiac Failure

Article	Year
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 11-05, Volume: 140, Issue:19 Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio. The Annals of pharmacotherapy, 2017, Volume: 51, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Piperidines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sitagliptin Phosphate; Uracil	2017
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study. Pharmacotherapy, 2018, Volume: 38, Issue:3 Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Retrospective Studies; Veterans	2018
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:6 Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil	2018
Saxagliptin Prevents Increased Coronary Vascular Stiffness in Aortic-Banded Mini Swine. Hypertension (Dallas, Tex. : 1979), 2018, Volume: 72, Issue:2 Topics: Adamantane; Animals; Aorta, Thoracic; Coronary Vessels; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Heart Failure; Ligation; Male; Stroke Volume; Swine; Swine, Miniature; Vascular Stiffness; Ventricular Remodeling	2018
Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. American journal of physiology. Heart and circulatory physiology, 2013, May-15, Volume: 304, Issue:10 Topics: Adamantane; Animals; Apoptosis; Blood Pressure; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Fibrosis; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Heart Rate; Hemodynamics; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Nitriles; Organ Size; Pyrrolidines; Real-Time Polymerase Chain Reaction; Survival; Vildagliptin	2013
Diabetes medications and heart failure: recognizing the risk. Circulation, 2014, Oct-28, Volume: 130, Issue:18 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2014
Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure? Prescrire international, 2014, Volume: 23, Issue:152 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Treatment Outcome	2014
Heart failure in SAVOR-TIMI 53: The hindsight of diabetic retinopathy. Journal of diabetes, 2015, Volume: 7, Issue:3 Topics: Adamantane; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans	2015
The Yin and the Yang of CV risks in patients with diabetes. The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No. Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2014
ACP Journal Club: in type 2 diabetes, saxagliptin increased HF hospitalizations, regardless of history of HF or CKD. Annals of internal medicine, 2015, Apr-21, Volume: 162, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation, 2015, Aug-11, Volume: 132, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation, 2015, Aug-11, Volume: 132, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. Diabetes care, 2016, Volume: 39, Issue:5 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2016
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:5 Topics: Adamantane; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Europe; Female; Heart Failure; Humans; Japan; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult	2016
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Annals of internal medicine, 2016, Jun-07, Volume: 164, Issue:11 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones	2016
No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan. International journal of cardiology, 2016, Oct-01, Volume: 220 Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Treatment Outcome; Vildagliptin	2016
Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation? International journal of cardiology, 2016, Oct-01, Volume: 220 Topics: Adamantane; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans	2016
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure. JAMA cardiology, 2016, 05-01, Volume: 1, Issue:2 Topics: Adamantane; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents	2016
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes care, 2016, Volume: 39 Suppl 2 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil	2016
Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients. Cardiovascular therapeutics, 2012, Volume: 30, Issue:5 Topics: Acetylcholine; Adamantane; Aged; Capillaries; Enzyme Inhibitors; Epoxide Hydrolases; Female; Heart Failure; Humans; Iontophoresis; Laser-Doppler Flowmetry; Lauric Acids; Male; Microcirculation; Middle Aged; Muscle Tonus; Muscle, Smooth, Vascular; Nitroprusside; Norepinephrine; Sample Size; Skin; Urotensins; Vasoconstrictor Agents; Vasodilator Agents	2012
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovascular diabetology, 2011, Sep-28, Volume: 10 Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Male; Myocardial Infarction; Nitriles; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Vildagliptin	2011
Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. Journal of molecular and cellular cardiology, 2012, Volume: 52, Issue:3 Topics: Adamantane; Animals; Coronary Circulation; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Heart Failure; Hemodynamics; Lauric Acids; Male; Myocardial Infarction; Myocardium; Nitric Oxide; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Ventricular Function, Left; Ventricular Remodeling	2012